Evidence map›Paper›PMID 42170012›Full record

ArticleChina CDC weekly2026

Post-Marketing Surveillance Data of Adverse Events Following Immunization with Human Rabies Vaccine - China, 2021-2024.

Lina Zhang, Keli Li, Yan Li, Chunxiang Fan, Yuan Li, Minrui Ren, Lei Cao, Wenzhou Yu, Zundong Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lina ZhangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Keli LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Yan LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Chunxiang FanNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Yuan LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Minrui RenNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Lei CaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Wenzhou YuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Zundong YinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: Human rabies vaccine has been in use for many years and has played a vital role in rabies prevention and control in China. What is added by this report?: From 2021 to 2024, the overall reported rate of adverse events following immunization (AEFI) with human rabies vaccine was 18.57 per 100,000 doses, of which 96.29% were common vaccine reactions. Rare vaccine reactions occurred at a rate of 0.49 per 100,000 doses; allergic rash was the most frequently reported rare reaction and usually was non-serious. The rate of rare and serious vaccine reactions was 0.07 per 100,000 doses. What are the implications for public health practice?: Human rabies vaccine, one of the most commonly used non-program vaccines in China, its AEFI rate fell within an acceptable range. Continued AEFI surveillance is essential for evaluating the post-marketing immnization safety of this vaccine.

Indexed as

Adverse Events Following ImmunizationHuman Rabies VaccinePost-marketing dataSurveillance

Identifiers

PMID42170012
PMCPMC13187652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.